Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-12 subunit beta, commonly known as p40, is a critical cytokine component that serves as a shared subunit for both Interleukin-12 (IL-12) and Interleukin-23 (IL-23) [UniProt, 2024]. When paired with the p35 subunit, it forms IL-12, which drives Type 1 T helper (Th1) cell differentiation; when paired with the p19 subunit, it forms IL-23, which is essential for the maintenance and expansion of Th17 cells [Nature, 2003]. This dual role makes the p40 subunit a central regulator of the inflammatory response, particularly in the IL-23/IL-17 signaling axis. Dysregulation and overproduction of p40-containing cytokines are strongly associated with the pathogenesis of chronic inflammatory conditions such as psoriasis, Crohn's disease, and ulcerative colitis [PubMed, 2021]. Therapeutic strategies targeting the p40 subunit, such as the monoclonal antibody ustekinumab, effectively neutralize both IL-12 and IL-23 signaling by preventing their binding to the IL-12 receptor beta 1 (IL-12Rβ1) chain [DrugBank, 2024]. This inhibition leads to a reduction in the production of downstream pro-inflammatory cytokines like interferon-gamma and IL-17, providing significant clinical benefit in autoimmune diseases [StatPearls, 2023].
Binds to the p40 subunit shared by the IL-12 and IL-23 cytokines, thereby preventing these cytokines from binding to their shared receptor, IL-12Rβ1, and inhibiting downstream signaling pathways such as JAK-STAT [DrugBank, 2024; StatPearls, 2023].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-12 subunit beta (p40) (IL-12B).